CLINICAL TRIAL PATIENT TECHNOLOGY INSIGHTS
-
Edge AI Is Reshaping How Clinical Trials Run
Edge computing and AI are transforming clinical trials – enabling real time monitoring, decentralized research, and faster, more cost-effective drug development.
-
Telehealth In Clinical Trials: What Sites And Patients Think
Sites and patients have complicated views on telehealth in trials. Here’s what the evidence shows about who benefits, who bears the burden, and where the limits are.
ECOA RESOURCES
-
Accelerate your eCOA assessment design to streamline UAT, mid-study updates, and protocol amendments effortlessly.
-
Join leading clinical experts as they debunk the top 5 myths about eCOA in 2025, separating fact from fiction to help clinical operations, procurement, and data management teams make smarter decisions.
-
Join Curebase CEO Tom Lemberg for a live demo of our next-generation ePRO/eCOA technology. See how our AI Assistant lets you build forms, generate translations, and enter data in seconds with our intuitive, user-friendly platform.
ECONSENT RESOURCES
-
Learn how eConsent digitalizes the trial participant consent process through increasingly simplified models designed to improve comprehension and boost engagement.
-
The shift towards decentralized and hybrid trials underscores the significance of EDC in expanding geographic reach, fostering diversity in participant populations, and reduce participant burden.
-
Delve into a variety of triggers for initiating re-consent, perspectives of regulators and IRBs regarding the re-consent process, and the role of digital processes in preventing issues related to re-consent.
EPRO RESOURCES
-
Learn how eConsent digitalizes the trial participant consent process through increasingly simplified models designed to improve comprehension and boost engagement.
-
The shift towards decentralized and hybrid trials underscores the significance of EDC in expanding geographic reach, fostering diversity in participant populations, and reduce participant burden.
-
In this presentation, a distinguished panel of experts illuminates the crucial role of patient-reported outcomes (PROs) in shaping regulatory decisions and drug development strategies.